WAVi is FDA 510(k) cleared (K213900) and TM-Flow runs on three cleared modules; each gives you quantified data that aids clinical decisions and does not replace them. WAVi reads brain function. TM-Flow reads cardiovascular plus autonomic. Max Pulse adds chairside pulse-wave screening, and PreCheckHealth panels add the molecular layer.
Two flagship platforms carry the diagnostic load. WAVi (FDA 510(k) K213900) measures brain function through EEG and event-related potentials. TM-Flow (LD Technology) reads cardiovascular plus autonomic function in one visit, built on three separately FDA 510(k)-cleared modules. Coverage for both is decided by the payer on the documented indication. Max Pulse and the PreCheckHealth genetic panels extend the picture without adding billing complexity.

Captures EEG and event-related potentials to aid in cognitive assessment, sports and injury baselining, and longitudinal brain monitoring. Retest frequency is decided by your payer on documented medical necessity. Wellness programs: before and after treatment, typically 4 to 6 weeks or 12 weeks.

One workstation, three modules: autonomic function, sudomotor response, and ankle-brachial index in a single ten-minute visit. Built on three separately FDA 510(k)-cleared modules (K173696, K152216, K200141).

Chairside pulse-wave screening for cardiovascular wellness markers. One-to-three-minute test, immediate report. A screening tool, not a replacement for formal cardiac workup.

Four clinical-grade panels: PharmacoCheck+, CancerCheck (116 genes), ImmunoCheck (291 genes), and Comprehensive Neurogenetic (203 genes). Provider-ordered through PreCheckHealth, not direct-to-consumer.
Diagnostics are not a one-time snapshot. They anchor the TITN methodology: capture an measured baseline, treat against what the data shows, then retest to show what changed. Instead of asking a patient whether they feel better, you show them, and their payer, exactly what changed.
FDA-cleared diagnostic captures quantified biomarkers: heart rate variability, sudomotor function, brain wave patterns, cognitive processing speed, evoked potentials. Documented before any intervention.
Evidence-based treatment protocol where applicable (ALTMS is FDA cleared for MDD), paired where appropriate with general-wellness modalities like photobiomodulation, hyperbaric, or hydrogen, tied to the baseline findings.
Identical protocol. Retest frequency is decided by your payer on documented medical necessity. Wellness programs: before and after treatment, typically 4 to 6 weeks (acute) or 12 weeks (chronic). Side-by-side reports show what changed.
Pick how you want to evaluate the diagnostics. No commitment past the first conversation.
Short platform demos of WAVi, TM-Flow, and Max Pulse are in production. Book a call or request a live demo in the meantime.
See it live on a call →Roberto or Weston takes the call personally. We'll walk you through devices, reimbursement, and onboarding for your specialty.
Pick a time →In-person across California, and nationally or internationally for larger engagements (travel quoted separately). Virtual screen-share anywhere else. We bring the device; you bring the questions.
Request a slot →Every FDA clearance and coverage statement on this page traces to a live primary source: the FDA 510(k) database (openFDA), CMS coverage and fee-schedule pages, and device manufacturers. TITN publishes no reimbursement figure on this site; coverage is decided by the payer. All diagnostics aid clinical decisions and do not replace clinical judgment.